Metuxtan Sr (Metformin Hydrochloride)

Metformin hydrochloride activates AMP‑activated protein kinase (AMPK), which suppresses hepatic gluconeogenesis and enhances peripheral glucose uptake. The combined effect reduces fasting and post‑prandial blood glucose without stimulating insulin secretion, making it useful for patients with insulin resistance.

The dose of Metuxtan Sr is individualized by the prescribing clinician based on the patient’s renal function, glycemic targets, and tolerability. Typical regimens start with a low dose that is gradually increased, but the exact amount and schedule must be determined by a qualified health professional.

Safety data for metformin during pregnancy are limited, and the pregnancy category is listed as unknown. It is generally used only when the potential benefit outweighs the risk. Metformin is excreted in breast milk, so breastfeeding mothers should consult their physician before using Metuxtan Sr.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metuxtan Sr (metformin) differs from sulfonylureas and insulin by not stimulating insulin secretion, which reduces the risk of hypoglycemia. Compared with newer agents such as SGLT2 inhibitors, metformin is less expensive and has a long safety record, though it may cause gastrointestinal upset more frequently.

Metuxtan Sr should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Metuxtan Sr is taken orally, usually with meals to lessen gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescribing clinician based on individual treatment goals.

The most serious adverse events include lactic acidosis, which can be life‑threatening, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic failure. Patients should be educated to seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, or severe skin rash.

Metuxtan Sr is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and known hypersensitivity to metformin. Caution is also advised for individuals with significant hepatic disease, heart failure, or those consuming excessive alcohol.